Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17301119 | 0.84 | FAAH (0.35) | LMNABLMFAAH | |
| SCHEMBL17301110 | 0.82 | ALDH1A1 (0.40) | LMNAALDH1A1BLMFAAH | |
| SCHEMBL17301116 | 0.81 | ALOX15 (0.37) | LMNAHTTMEN1KMT2AFAAH | |
| SCHEMBL17301122 | 0.80 | FAAH (0.36) | ALDH1A1USP2MEN1KMT2AFAAH | |
| SCHEMBL17301109 | 0.79 | PRKCA (0.34) | LMNAFAAH | |
| SCHEMBL17301113 | 0.78 | KMT2A (0.45) | LMNAALDH1A1SMN1; SMN2USP2HTT | |
| SCHEMBL17301126 | 0.77 | ALDH1A1 (0.38) | LMNAALDH1A1USP2HTTMEN1 | |
| SCHEMBL17301131 | 0.75 | SMN1; SMN2 (0.40) | LMNAALDH1A1SMN1; SMN2HTTNPSR1 | |
| SCHEMBL17301127 | 0.75 | TDP1 (0.48) | LMNAALDH1A1USP2HTTKMT2A | |
| SCHEMBL17301123 | 0.74 | TAAR1 (0.34) | LMNAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344426-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344426-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | LMNA 4409/4885HSP90AA1 608/4885ALDH1A1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.